Dual mechanism of tumor selectivity
Limits toxicity to normal tissues

No linker instability
Reduced on-target off-tumor toxicity vs ADCs

Active delivery from endosome to cytosol
Enhanced cytosolic delivery and thus potency

Efficacy even at low target density
Broader patient population than ADCs

Lack of liver clearance
Enhanced tumor delivery compared to LNPs

Suitable for both protein and RNA delivery
Wide range of applications beyond Oncology

Ease of manufacture
Lower cost of goods compared to ADCs